NGM Biopharmaceuticals. has filed a patent for binding agents, like antibodies, that target ILT2, ILT4, or both. The patent also covers related polynucleotides, vectors, and cells containing these agents. The claim specifies a binding agent that targets both ILT2 and ILT4. GlobalData’s report on NGM Biopharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on NGM Biopharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. NGM Biopharmaceuticals's grant share as of January 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
Binding agent for ilt2 and ilt4 in antibodies
A recently filed patent (Publication Number: US20240025997A1) discloses a binding agent designed to target human immunoglobulin-like transcript 2 (ILT2) and human immunoglobulin-like transcript 4 (ILT4). The binding agent comprises an antigen-binding domain with specific sequences for both ILT2 and ILT4. The patent details the amino acid sequences of the heavy chain variable region and light chain variable region that make up the antigen-binding domain, providing multiple variations for each region to target ILT2 and ILT4 effectively. Additionally, the patent covers various properties and applications of the binding agent, including its use as an antibody, recombinant antibody, chimeric antibody, or humanized antibody, among others. The binding agent is also described to have potential therapeutic applications in cancer treatment by disrupting the interaction between ILT2 and ILT4 with MHC Class I molecules, inhibiting their activity, and enhancing immune responses against tumors.
Furthermore, the patent outlines methods for using the binding agent in disrupting ILT2 and ILT4 activities, inhibiting tumor growth, enhancing immune responses, and treating various types of cancer, such as mesothelioma, glioblastoma, renal cell carcinoma, and breast cancer. The patent also suggests combination therapies involving the binding agent and additional therapeutic agents, such as anti-PD-1 or anti-PD-L1 antibodies, to improve treatment outcomes. Overall, the patent provides a comprehensive overview of the binding agent's design, properties, and potential applications in cancer therapy, highlighting its role in modulating immune responses and targeting specific immune checkpoints to combat cancer effectively.
To know more about GlobalData’s detailed insights on NGM Biopharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
